investorscraft@gmail.com

Intrinsic Value of Axsome Therapeutics, Inc. (AXSM)

Previous Close$105.44
Intrinsic Value
Upside potential
Previous Close
$105.44

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders. The company’s revenue model is driven by its commercialized products, including Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness, alongside a pipeline of late-stage CNS candidates. Axsome operates in the highly competitive neuroscience sector, where innovation and differentiation are critical to capturing market share. The company positions itself as a leader in addressing unmet medical needs through its differentiated mechanisms of action and patient-centric approach. Its strategic focus on CNS disorders, a market with significant growth potential due to rising mental health awareness, provides a robust foundation for long-term value creation. Axsome’s ability to advance its clinical pipeline while scaling commercialization efforts underscores its potential to solidify its market position.

Revenue Profitability And Efficiency

Axsome reported revenue of $385.7 million for FY 2024, reflecting growth from its commercial products. However, the company posted a net loss of $287.2 million, with diluted EPS of -$5.99, indicating ongoing investment in R&D and commercialization. Operating cash flow was negative at $128.4 million, highlighting the capital-intensive nature of its biopharmaceutical operations. Capital expenditures were negligible, suggesting a lean operational approach.

Earnings Power And Capital Efficiency

The company’s earnings power remains constrained by high R&D and commercialization costs, typical for a growth-stage biopharma firm. With no dividends and significant reinvestment into its pipeline, Axsome’s capital efficiency is focused on long-term value creation rather than near-term profitability. The negative EPS and operating cash flow underscore the transitional phase of scaling its commercial footprint.

Balance Sheet And Financial Health

Axsome’s balance sheet shows $315.4 million in cash and equivalents against $193.0 million in total debt, providing a liquidity cushion for near-term operations. The debt level is manageable relative to its cash position, but sustained losses may necessitate additional financing. The absence of capital expenditures suggests prudent cash management amid growth investments.

Growth Trends And Dividend Policy

Revenue growth is driven by the commercialization of Auvelity and Sunosi, with potential upside from pipeline advancements. The company does not pay dividends, reinvesting all cash flows into R&D and market expansion. Future growth hinges on successful clinical trials and broader adoption of its therapies, particularly in the underserved CNS market.

Valuation And Market Expectations

The market likely values Axsome based on its growth potential in CNS therapeutics rather than current profitability. The negative EPS reflects high expectations for pipeline success and commercial execution. Investors may focus on upcoming clinical milestones and revenue traction as key valuation drivers.

Strategic Advantages And Outlook

Axsome’s strategic advantages include its differentiated CNS portfolio and first-mover potential in niche indications. The outlook depends on execution in commercialization and pipeline development, with risks tied to clinical outcomes and competitive pressures. Long-term success will hinge on translating innovation into sustainable revenue growth and eventual profitability.

Sources

Company filings, CIK 0001579428

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount